IBJNews

Setbacks in diabetes market batter Roche

Back to TopCommentsE-mailPrintBookmark and Share

Roche Diagnostics Corp., once the darling of the U.S. diabetes-device market, is now licking its wounds.

And it’s mulling whether to keep fighting on all fronts or to pull back.

The Switzerland-based company, which runs its U.S. operations out of Indianapolis, has for at least five years suffered swooning share in the markets for blood glucose monitors and insulin pumps.

The American troubles haven’t slowed Roche globally, where it continues to grow faster than its competitors. But with a new chief of diagnostics named in Switzerland in September, analysts foresee difficult cuts soon for Roche’s U.S. diabetes business.

The most immediate decision on the table is whether to keep selling insulin pumps in the United States. In April, the U.S. Food and Drug Administration required the company to recall its Spirit insulin pumps, threatening to further dampen the product's already weak sales.

“We don’t see the company putting the same resources in the field as they have in Europe,” wrote Kelly Close, president of San Francisco-based market analysis firm Close Concerns, in an e-mail about Roche's insulin pumps. “It has been difficult for Roche to differentiate in the U.S., for sure.”

Local Roche executives declined to be interviewed for this story. But current and former employees and contractors at Roche say the company is evaluating all its locations around the globe in the wake of its $46 billion buyout this year of California-based drugmaker Genentech Inc.

Most of that work is on the pharmaceutical side of the business, which accounts for 80 percent of Roche’s revenue. But the company is reviewing all its assets, according to people with knowledge of the process.

No decisions have been announced, but among the possibilities being considered are moving research and development jobs from Indianapolis to the West Coast and moving information technology jobs from the East Coast to Indianapolis.

The stakes are big for the Indianapolis area. Roche is one of the area’s 15 largest employers, sustaining 2,900 well-paying jobs at campuses in Indianapolis and Fishers.

Roche’s history in Indianapolis dates to the 1964 founding of Bio-Dynamics, a diagnostic and medical-device company. It was purchased 10 years later by Germany-based Boehringer Mannheim Corp., which then moved its U.S. headquarters from New York City to Indianapolis.

Roche acquired Boehringer in 1998 to form the world’s largest diagnostic company. Roche has added nearly 1,000 jobs here in the last decade.

But employment trends recently have moved the other way. Last year, Roche said 300 jobs connected to its lab equipment business would move to Germany by 2011. Many of the people in those jobs, which were both scientific and business positions, were given the chance to find other jobs with Roche’s U.S. locations.

When Daniel O’Day, a 22-year Roche veteran, becomes chief of the global diagnostics business Jan. 1, company insiders expect further changes.

Slower growth

Diabetes accounts for the largest chunk of Roche’s local operations. But the outpost here manages sales and marketing of all of Roche’s diagnostics throughout North America. Those products include laboratory testing machines and supplies, DNA-based tests for various diseases, and patient monitoring equipment used by doctors and hospitals.

Roche’s diagnostic sales in North America grew 4 percent through the first nine months of this year, to roughly $1.9 billion. But Roche’s worldwide diagnostic sales are growing twice as fast.

In the U.S., Roche’s diabetes sales have fallen 2 percent so far this year, according to Close Concerns.

The insulin pump unit, called Disetronic, has been dogged by problems since the day Roche spent $1.2 billion to acquire it in 2003. The FDA said the company’s factory in Switzerland wasn’t up to snuff, which kept Disetronic pumps off the market for roughly two years. Their sales never recovered.

Disetronic’s 20-percent U.S. market share in 2001 collapsed to less than 4 percent by 2007, according to Toronto-based Millennium Research Group.

The insulin-pump woes prompted Roche to start handing out layoff notices this fall, according to people with knowledge of the dismissals. This month, company brass were scheduled to meet to consider whether to exit the U.S. market, according to David Kliff, publisher of the Diabetic Investor newsletter.

“All signs point to that,” he said. “My sense is, [O’Day] is going to say, ‘Why throw good money after bad?’”

The Disetronic unit employed about 200 people at its Fishers headquarters. This fall, Roche decided to change the Disetronic name to Roche.

But the Roche name isn’t what it was just five years ago in the diabetes market, Kliff said. Since then, Roche has lost about a third of its U.S. market share.

Roche held 27 percent of the U.S. glucose-meter market in 2004, according to Close Concerns. But that slid to less than 21 percent now.

“At one time, they were on top of the world. But they didn’t adapt to the changes. And that really hurt them,” Kliff said.

Early innovations

Roche delivered several market-leading innovations in the 1990s and early 2000s.

It was the first to introduce curved strips for its glucose meters, which were designed to fit patients’ fingers better and make it easier to get adequate blood on the strip to conduct a test. And in 2002, Roche won a retailers’ award for its Accu-Check Compact, which featured push-button dispensing of test strips.

But now the entire market has become less profitable. Retailers and health insurers pushed back on the pricing of glucose monitors, which at one time had 90-percent profit margins, Kliff said. Also, several retailers started selling store-brand glucose meters at lower prices.

Roche was loath to discount its products, but LifeScan, a unit of New Jersey-based Johnson & Johnson, was not. LifeScan scored more favorable arrangements with health insurers, and has seen its market share surge at Roche’s expense.

Roche has a new glucose meter, the Accu-Chek Aviva Nano, ready for the U.S. market. It already has been selling well overseas. But this summer, the FDA told Roche officials they would not approve the Nano.

The FDA worries because the enzyme Roche’s glucose monitors use fails to distinguish between glucose and other sugars. In a very small number of cases, this enzyme has led to a glucose reading higher than reality. When this has occurred in hospitals, the patients were sometimes given far larger doses of insulin than necessary, which caused six deaths in the last two years.

Meanwhile, real growth in the market is coming from continuous glucose monitors, which patients can attach for several days to see how their glucose levels rise and fall.

But Roche does not have such a product in the U.S. market.

Competitors such as Medtronic Inc. have even introduced continuous glucose monitors that link to insulin pumps. These devices have the potential for strong sales, said James Kurz, a vascular analyst at Millennium Research Group.

“Combination devices are the way to go in the future,” he said.

Roche introduced a combination product in Europe this year. But with its insulin pumps selling so poorly in the United States, Kliff does not expect Roche to ever get a combination product onto the market here.

But Bruce Frank, a former Roche employee and now a consultant to medical-device companies, said not to count Roche out. The current combo products are not accurate or fast enough to make insulin pumping automatic, but Roche’s engineers in Germany have a history of turning out breakthroughs.

“It’s a very strong company; it’s got a lot of money,” Frank said. “It can do what it wants to do when it wants to do it.” •

ADVERTISEMENT

  • This is depressing
    I think this one is slanted or at least hope so

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Uh, sorry Johnnie, but you are incorrect. Despite the assertions by yourself and various defenders and captains, sports attendance is NOT off significantly at most sporting events in the US. Variances in attendance has been in the range of single digits, both + & - for years now. MLB has had most of its best overall attendance nubers in the last decade, and that trend has been consistent for most major sporting events. The number one issue cited by most fans when asked about attendance is the overall cost of attending. The presence of HD and big screen televisions in home doesn't even register, as a factor for not attending an event. VALUE in the product is the key, and apparently is something lacking in the current ICS. What other explanation is there when with what is routinely touted as the "best" racing on the planet, fans are staying away in DROVES. A "close" title battle into the last event at Fontana, with the "cars and stars" of the ICS, and who showed up? MAYBE 8K. Sorry, but HD TV isn't to blame for that kind of fan apathy.

  2. Do you need finance to establish your business ? Are you interested in getting a loan at 3% from our private company? If so please Email: suntrust_oil@blumail.org

  3. If she was worth the $ the public outcry over direct tv dropping them would have kept them on their dishes as we have seen with other companies. I too quit watching channel 13 after she showed up since I left channel 8 because of her all show rather than production results. When Randy on 8 corrected her she had a big head and incorrectly challenged his correction for pronunciation of a city. Other antics while she matures was too much for me with her very inaccurate forecasts. All the forecasters were predicting rain until Thursday except Chris. They predicted sunny on Thursday but instead of rain until Thursday upon which the sun would finally make it out in full glory Chris was right on the money just as I too predicted looking at the radar on weather.gov. One thing I love about Angela is the fear you can see in her every time it thunders in the winter. It far exceeds the entertainment value of her body language (high heel noise drags, depression, etc) when her forecasts are so incorrect. Her hair stands on end, you have to see it!!!

  4. Good Day, Apply For A Loan I am Mr Fernadez Antonio, a private Loan lender and a cooperate financial for real estate and any kinds of business financing. I also offer Loans to individuals, Firms and cooperate bodies at 3% interest rate We offer any kind of loans. email us via fernadezloaninvest@outlook.com LOAN APPLICATION FORM First name:......................... Middle name:......................... Last name:........................................ Date of birth (yyyy-mm-dd):....................... Gender:........................................... Marital status:................................... Total Amount Needed............................... Loan Duration.................................... Address:.......................................... City:............................................. State/province:................................... Zip/postal code:.................................. Country:.......................................... Phone:............................................ Fax:.............................................. Mobile/cellular:.................................. Monthly Income.................................... Occupation:....................................... Best Regard, Mr Fernadez Antonio.

  5. i will love to share my testimony to you all the people in world i got married to my husband about 2 year ago we start having problems at home like we stop sleeping on the same bed,fighting about little things he always comes home late at night,drinking too much and sleeping with other women out side i have never love any man in my life except him. he is the father of my child and i don't want to loose him because we have worked so hard together to become what we are and have today .few month ago he now decided to live me and the kid,being a single mother can be hard sometimes and so i have nobody to turn to and i was heart broken.i called my mom and explain every thing to her,my mother told me about DR.okoro how he helped her solve the problem between her and my dad i was surprise about it because they have been without each other for three and a half years and it was like a miracle how they came back to each other. i was directed to DR. okoro on his email:okorospell@gmail.com and explain everything to him,so he promise me not to worry that he will cast a spell and make things come back to how we where so much in love again and that it was another female spirit that was controlling my husband he told me that my problem will be solved within two days if i believe i said OK So he cast a spell for me and after two days my love came back asking me to forgive him i Am so happy now. so that why i decided to share my experience with every body that have such problem contact Dr okoro the great spell caster on his email addresses spellcasterforlove@outlook.com

ADVERTISEMENT